-
3
-
-
5044235632
-
Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
-
DOI 10.1039/b402150a
-
Ö Almarsson MJ Zaworotko 2004 Chem Commun 17 1889 1896 10.1039/b402150a (Pubitemid 39335992)
-
(2004)
Chemical Communications
, Issue.17
, pp. 1889-1896
-
-
Almarsson, O.1
Zaworotko, M.J.2
-
4
-
-
66849083715
-
-
10.1021/cg900129f 1:CAS:528:DC%2BD1MXkslarsL4%3D
-
N Schultheiss A Newman 2009 Cryst Growth Des 9 2950 10.1021/cg900129f 1:CAS:528:DC%2BD1MXkslarsL4%3D
-
(2009)
Cryst Growth des
, vol.9
, pp. 2950
-
-
Schultheiss, N.1
Newman, A.2
-
6
-
-
37049165561
-
-
10.1039/jr9480000061 1:STN:280:DyaH1c%2FkslCktw%3D%3D
-
HM Powell 1948 J Chem Soc 16 61 73 10.1039/jr9480000061 1:STN:280:DyaH1c%2FkslCktw%3D%3D
-
(1948)
J Chem Soc
, vol.16
, pp. 61-73
-
-
Powell, H.M.1
-
9
-
-
0000284299
-
-
10.1002/hlca.19910740623 1:CAS:528:DyaK3MXmsFGmt78%3D
-
O Ermer 1991 Helv Chim Acta 74 1339 10.1002/hlca.19910740623 1:CAS:528:DyaK3MXmsFGmt78%3D
-
(1991)
Helv Chim Acta
, vol.74
, pp. 1339
-
-
Ermer, O.1
-
10
-
-
0000143697
-
-
10.1021/ja00075a024 1:CAS:528:DyaK3sXmsF2qsb8%3D
-
O Ermer C Röbke 1993 J Am Chem Soc 115 10077 10.1021/ja00075a024 1:CAS:528:DyaK3sXmsF2qsb8%3D
-
(1993)
J Am Chem Soc
, vol.115
, pp. 10077
-
-
Ermer, O.1
Röbke, C.2
-
11
-
-
0004912089
-
-
10.1063/1.480645 1:CAS:528:DC%2BD3cXitlSgtg%3D%3D
-
K Hermansson 2000 J Chem Phys 112 835 10.1063/1.480645 1:CAS:528:DC%2BD3cXitlSgtg%3D%3D
-
(2000)
J Chem Phys
, vol.112
, pp. 835
-
-
Hermansson, K.1
-
13
-
-
0033988596
-
Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate
-
DOI 10.1016/S0378-5173(99)00315-4, PII S0378517399003154
-
Y Kobayashi S Ito S Itai K Yamamoto 2000 Int J Pharm 193 137 10.1016/S0378-5173(99)00315-4 1:CAS:528:DyaK1MXnvFSltrw%3D (Pubitemid 30001856)
-
(2000)
International Journal of Pharmaceutics
, vol.193
, Issue.2
, pp. 137-146
-
-
Kobayashi, Y.1
Ito, S.2
Itai, S.3
Yamamoto, K.4
-
17
-
-
0034256996
-
Solid-state study of polymorphic drugs: Carbamazepine
-
DOI 10.1016/S0731-7085(00)00262-4, PII S0731708500002624
-
C Rustichelli G Gamberini V Ferioli MC Gamberini R Ficarra S Tommasini 2000 J Pharm Biomed Anal 23 41 10.1016/S0731-7085(00)00262-4 1:CAS:528:DC%2BD3cXktlCrtrw%3D (Pubitemid 30394550)
-
(2000)
Journal of Pharmaceutical and Biomedical Analysis
, vol.23
, Issue.1
, pp. 41-54
-
-
Rustichelli, C.1
Gamberini, G.2
Ferioli, V.3
Gamberini, M.C.4
Ficarra, R.5
Tommasini, S.6
-
20
-
-
0001418924
-
-
10.1002/crat.2170211118 1:CAS:528:DyaL2sXlvFarsg%3D%3D
-
G Reck G Dietz 1986 Cryst Res Technol 21 1463 10.1002/crat.2170211118 1:CAS:528:DyaL2sXlvFarsg%3D%3D
-
(1986)
Cryst Res Technol
, vol.21
, pp. 1463
-
-
Reck, G.1
Dietz, G.2
-
21
-
-
0345305385
-
Crystal Engineering of the Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids Involving Carbamazepine
-
DOI 10.1021/cg034035x
-
SG Fleischman SS Kuduva JA McMahon B Moulton RDB Walsh N Rodriguez-Hornedo MJ Zaworotko 2003 Cryst Growth Des 3 909 10.1021/cg034035x 1:CAS:528:DC%2BD3sXksF2kt7k%3D (Pubitemid 37474229)
-
(2003)
Crystal Growth and Design
, vol.3
, Issue.6
, pp. 909-919
-
-
Fleischman, S.G.1
Kuduva, S.S.2
McMahon, J.A.3
Moulton, B.4
Bailey Walsh, R.D.5
Rodriguez-Hornedo, N.6
Zaworotko, M.J.7
-
23
-
-
45749085730
-
-
10.1039/b715396a 1:CAS:528:DC%2BD1cXotF2ns7Y%3D
-
SL Childs N Rodríguez-Hornedo LS Reddy A Jayasankar C Maheshwari L McCausland R Shipplett BC Stahly 2008 CrystEngComm 10 856 10.1039/b715396a 1:CAS:528:DC%2BD1cXotF2ns7Y%3D
-
(2008)
CrystEngComm
, vol.10
, pp. 856
-
-
Childs, S.L.1
Rodríguez-Hornedo, N.2
Reddy, L.S.3
Jayasankar, A.4
Maheshwari, C.5
McCausland, L.6
Shipplett, R.7
Stahly, B.C.8
-
24
-
-
34250862709
-
Performance comparison of a co-crystal of carbamazepine with marketed product
-
DOI 10.1016/j.ejpb.2006.12.016, PII S093964110600378X
-
MB Hickey ML Peterson LA Scoppettuolo SL Morrisette A Vetter H Guzmán JF Remenar Z Zhang MD Tawa S Haley MJ Zaworotko Ö Almarsson 2007 Eur J Pharm Biopharm 67 112 10.1016/j.ejpb.2006.12.016 1:CAS:528: DC%2BD2sXntF2mtbs%3D (Pubitemid 46991320)
-
(2007)
European Journal of Pharmaceutics and Biopharmaceutics
, vol.67
, Issue.1
, pp. 112-119
-
-
Hickey, M.B.1
Peterson, M.L.2
Scoppettuolo, L.A.3
Morrisette, S.L.4
Vetter, A.5
Guzman, H.6
Remenar, J.F.7
Zhang, Z.8
Tawa, M.D.9
Haley, S.10
Zaworotko, M.J.11
Almarsson, O.12
-
25
-
-
80055000890
-
-
The Merck Index, 13th edn; Merck & Co., Inc.: Whitehouse Station, NJ, 2001; p 1342, and UCB homepage:
-
The Merck Index, 13th edn; Merck & Co., Inc.: Whitehouse Station, NJ, 2001; p 1342, and UCB homepage: http://www.ucbpharma.com/about-ucb
-
-
-
-
26
-
-
34347211818
-
-
10.1021/cg0607710 1:CAS:528:DC%2BD2sXltFCjs7g%3D
-
FP Fabbiani DR Allan WIF David AJ Davidson AR Lennie S Parsons CR Pulham JE Warren 2007 Cryst Growth Des 7 1115 10.1021/cg0607710 1:CAS:528: DC%2BD2sXltFCjs7g%3D
-
(2007)
Cryst Growth des
, vol.7
, pp. 1115
-
-
Fabbiani, F.P.1
Allan, D.R.2
David, W.I.F.3
Davidson, A.J.4
Lennie, A.R.5
Parsons, S.6
Pulham, C.R.7
Warren, J.E.8
-
30
-
-
27744518934
-
Achieving polymorphic and stoichiometric diversity in cocrystal formation: Importance of solid-state grinding, powder X-ray structure determination, and seeding
-
DOI 10.1021/cg0501682
-
AV Trask J van de Streek WDS Motherwell W Jones 2005 Cryst Growth Des 5 2233 10.1021/cg0501682 1:CAS:528:DC%2BD2MXhtVequrbE (Pubitemid 41619316)
-
(2005)
Crystal Growth and Design
, vol.5
, Issue.6
, pp. 2233-2241
-
-
Trask, A.V.1
Van De Streek, J.2
Motherwell, W.D.S.3
Jones, W.4
|